Metronomic cyclophosphamide and methotrexate for breast cancer: Enhanced efficacy by adding dalteparin and low-dose prednisone?

Breast

Volumn 20, Issue 5, 2011, Pages 483-484

  Buckman, Robert ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DALTEPARIN; DOCETAXEL; EXEMESTANE; FULVESTRANT; LETROZOLE; METHOTREXATE; PREDNISONE; TAMOXIFEN;

ADULT; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CASE REPORT; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; LETTER; LOW DRUG DOSE; LUNG METASTASIS; LYMPH NODE METASTASIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL;

EID: 80052444331     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2011.06.003     Document Type: Letter

References (4)

1. Colleoni M., Rocca A., Sandri M.T., Zorzino L., Masci G., Nolè F., et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002, 13:73-80.
2. Soon Wong Nan, Buckman Robert A., Clemons Mark, Verma Shailendra, Dent Susan, Trudeau Maureen E., et al. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response. J Clin Oncol February 10, 2010, 28(5):723-730.
3. Norrby K., Nordenheim A. Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vitro. APMIS 2010, 10.1111/j.1600-0463.2010.02635.
4. Emmenegger U., Francis G., Chow A., Shaked Y., Kouri A., Man S., et al. Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide. Neoplasia 2011 Jan, 13(1):40-48.